Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
November 4th, 2021
2.7K views
Myocardial infarction (MI) animal models that emulate the natural process of the disease in humans are crucial to understanding pathophysiological mechanisms and testing the safety and efficacy of new emergent therapies. Here, we describe an MI swine model created by deploying a percutaneous embolization coil.
Overview
This article presents a myocardial infarction (MI) model in swine that closely mimics human disease, facilitating the study of pathophysiological mechanisms and therapeutic interventions. The model utilizes a percutaneous embolization coil, avoiding traditional open-chest surgery.
Key Study Components
Area of Science
- Cardiovascular research
- Animal modeling
- Translational medicine
Background
- Myocardial infarction is a leading cause of morbidity and mortality.
- Animal models are essential for understanding disease mechanisms.
- Traditional models often involve invasive surgery, leading to complications.
- A less invasive approach can improve reproducibility and relevance.
Purpose of Study
- To develop a swine model of MI that reflects human pathology.
- To provide a method that minimizes postoperative inflammation.
- To enhance the feasibility of MI studies in a laboratory setting.
Methods Used
- Animal preparation under anesthesia.
- Placement of electrocardiogram probes for monitoring.
- Deployment of a percutaneous embolization coil.
- Assessment of ischemic area and heart function.
Main Results
- The model successfully induced myocardial infarction.
- Electrocardiogram changes were recorded during the procedure.
- Postoperative inflammation was significantly reduced.
- The model demonstrated high reproducibility for future studies.
Conclusions
- The swine MI model is a valuable tool for cardiovascular research.
- This method can lead to better understanding of MI and potential therapies.
- Future studies can build on this model to explore new treatments.
Frequently Asked Questions
What is the significance of using a swine model for MI?
Swine models closely resemble human physiology, making them ideal for studying myocardial infarction.
How does this model reduce postoperative complications?
By avoiding open-chest surgery, the model minimizes inflammation and recovery time.
What monitoring techniques are used during the procedure?
Electrocardiogram probes are placed to monitor heart activity throughout the experiment.
Can this model be used for testing new therapies?
Yes, it provides a platform for evaluating the safety and efficacy of new treatments.
What are the main advantages of this MI model?
It is less invasive, reproducible, and closely mimics human myocardial infarction.
Is this model suitable for long-term studies?
Yes, it allows for extended observation of cardiac function and recovery.
Executive Industry Relevance
Reliable large-animal myocardial infarction (MI) models are essential for translational cardiovascular drug and cell therapy development. The percutaneous coil deployment in swine enables reproducible, clinically relevant MI induction without open-chest surgery, supporting predictive confidence in preclinical efficacy and safety studies. This model strengthens the translational bridge from discovery to preclinical validation for novel cardiac interventions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of cardiac injury mechanisms in a system closely mirroring human physiology.
- Supports functional validation of therapeutic targets in post-MI remodeling and heart failure progression.
- Facilitates mechanistic de-risking for candidate interventions prior to clinical translation.
Screening & Assay Development
- Provides a standardized, reproducible platform for evaluating therapeutic efficacy in a disease-relevant context.
- Enables quantitative assessment of infarct size and cardiac function using imaging and histology.
- Supports assay development for biomarkers of myocardial injury and repair.
Translational & Preclinical Research
- Aligns with human cardiac anatomy and healing, enhancing predictive value for translational studies.
- Allows for acute, sub-acute, and chronic MI modeling to assess therapeutic durability and safety.
- Facilitates risk-adjusted advancement decisions for cell, gene, and pharmacological therapies.
Pipeline & Workflow Integration
This swine MI model integrates into the preclinical continuum from target validation through lead optimization and translational research.
- Discovery Biology: Supports hypothesis testing on cardiac injury and repair mechanisms in a human-relevant system.
- Screening: Enables reproducible, quantitative evaluation of candidate therapies in vivo.
- Analytics: Provides imaging and histological endpoints for comparative analysis of intervention effects.
- Translational Research: Bridges discovery findings to preclinical validation with high anatomical and physiological relevance.
- Enterprise Reuse: Offers a scalable, standardized platform for ongoing cardiovascular R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac therapeutic development.
- Operational Value: Delivers reproducibility, standardization, and scalability for cross-study comparisons.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardiovascular assets.
Implementation Considerations
- Requires expertise in interventional cardiology and large-animal anesthesia.
- Needs access to fluoroscopy, angiography, and advanced imaging infrastructure.
- Demands rigorous cross-team standardization for reproducibility and data comparability.
- Adaptation may be needed for different coronary territories or MI severities.
- Mortality and complication rates must be managed and transparently reported.
Biopharma FAQs
Why does null hypothesis testing matter for infarct size quantification?
Null hypothesis testing in infarct size quantification ensures that observed differences in therapeutic outcomes are statistically significant, supporting robust target validation and reducing false positives in preclinical cardiac studies.
How does independent variable isolation in coil deployment fit the discovery pipeline?
Isolating the site and extent of coil-induced occlusion allows precise control of the ischemic insult, enabling systematic evaluation of therapeutic interventions and mechanistic hypotheses within the discovery and validation workflow.
What do quantitative dependent variable measurements enable in this MI model?
Quantitative measurements such as infarct size by imaging and histology enable objective comparison of intervention effects, supporting data-driven advancement decisions and cross-study reproducibility in cardiovascular R&D.
Why are replication requirements critical for cross-functional collaboration in preclinical MI studies?
Replication ensures that findings from the swine MI model are robust and transferable across teams, facilitating reliable data integration and collaborative decision-making in multi-disciplinary drug development programs.
What statistical analysis capabilities are required before implementing efficacy studies in this model?
Robust statistical analysis, including power calculations and appropriate significance testing, is essential to validate therapeutic effects and ensure that preclinical efficacy studies in the swine MI model yield actionable, reproducible results for pipeline progression.
Chapters in this video
0:04
Introduction
0:50
Hemodynamic Monitoring and Preparation of the Surgical Area
1:57
Vascular Access
2:36
Coronary Angiography
3:31
Coil Implantation
4:12
Results: Pre-and Post-Coil Deployment Analysis Using Coronary Angiography, MRI, and Cardiac Tissue Sections
5:15
Conclusion
